KR102310898B1 - Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus - Google Patents
Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus Download PDFInfo
- Publication number
- KR102310898B1 KR102310898B1 KR1020210020494A KR20210020494A KR102310898B1 KR 102310898 B1 KR102310898 B1 KR 102310898B1 KR 1020210020494 A KR1020210020494 A KR 1020210020494A KR 20210020494 A KR20210020494 A KR 20210020494A KR 102310898 B1 KR102310898 B1 KR 102310898B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- lactobacillus acidophilus
- present
- antioxidant
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 42
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 39
- 229940039695 lactobacillus acidophilus Drugs 0.000 title claims abstract description 39
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 29
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 19
- 235000006708 antioxidants Nutrition 0.000 title description 15
- 239000000843 powder Substances 0.000 title description 8
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 230000014509 gene expression Effects 0.000 claims abstract description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 7
- 101150071146 COX2 gene Proteins 0.000 claims abstract description 5
- 101150109636 Inos gene Proteins 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims description 5
- 210000003608 fece Anatomy 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 34
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 28
- 241000894006 Bacteria Species 0.000 abstract description 17
- 235000014655 lactic acid Nutrition 0.000 abstract description 17
- 239000004310 lactic acid Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002292 Radical scavenging effect Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000010438 heat treatment Methods 0.000 abstract description 6
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 241000186840 Lactobacillus fermentum Species 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000186606 Lactobacillus gasseri Species 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- -1 peroxynitrite anion Chemical class 0.000 description 10
- 240000006024 Lactobacillus plantarum Species 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 6
- 241000186605 Lactobacillus paracasei Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 240000002605 Lactobacillus helveticus Species 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000186869 Lactobacillus salivarius Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000005839 radical cations Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
Abstract
Description
본 발명은 항산화 활성을 갖는 신규한 유산균에 관한 것으로, 보다 구체적으로는 락토바실러스 애시도필러스 MG4559 균주를 포함하는 항산화용 조성물에 관한 것이다. The present invention relates to novel lactic acid bacteria having antioxidant activity, and more particularly, to an antioxidant composition comprising the Lactobacillus acidophilus MG4559 strain.
염증은 신체의 외부 신체적 상해 또는 미생물의 생체 내 감염으로부터 신체를 보호하기 위한 비특이적 방어 작용이다. 이원자 자유 라디칼인 산화질소(nitric oxide; NO)는 염증반응의 대표적인 지표이다. 산화질소는 생체 내 산화질소 합성효소(nitric oxide synthase; NOS)에 의해 L-아르기닌(L-arginine)으로부터 생성된 고반응성의 자유 라디칼이다 [Lee et al., 1999]. 산화질소는 생리적 현상, 혈압 조절 및 신경 전달 물질로서 작용하며, 혈전 면역 기능으로 작용하는 것으로 알려져 있다 [Lee et al., 2000; Seo et al., 2001].Inflammation is a non-specific defense action to protect the body from external bodily injury or in vivo infection of microorganisms. Nitric oxide (NO), a diatomic free radical, is a representative indicator of an inflammatory response. Nitric oxide is a highly reactive free radical generated from L-arginine by nitric oxide synthase (NOS) in vivo [Lee et al., 1999]. Nitric oxide is known to act as a physiological phenomenon, blood pressure regulation, and neurotransmitter, and acts as a thrombus immune function [Lee et al., 2000; Seo et al., 2001].
그러나 산화질소가 필요 이상으로 생성되면 염증반응을 일으키고 면역계의 조직 파괴 및 이상을 나타낸다. 산화질소는 염증반응을 위한 매개체이며, 시간이 지남에 따라 아질산염(nitrite; NO2), 질산염(nitrate; NO3)과 같은 안정한 화합물로 존재하는 것으로 알려져 있는데, 여기서 퍼옥시나이트라이트 음이온(ONOO-)은 염증성이며, 세포 내 독소를 유발하고, 이는 조직 손상의 원인이 된다[Szabo et al., 1996].However, when nitric oxide is produced more than necessary, it causes an inflammatory response and causes tissue destruction and abnormalities in the immune system. Nitric oxide is a mediator for the inflammatory reaction and is known to exist as stable compounds such as nitrite (NO2) and nitrate (NO3) over time, where the peroxynitrite anion (ONOO-) is It is inflammatory and induces endotoxin, which causes tissue damage (Szabo et al., 1996).
또한, 신체의 과도한 활성산소(Reactive oxygen species: ROS)는 산화 스트레스를 유발하고 염증 질환, 패혈증, 암, 노화, 피부 노화, 근감소증, 자가면역 질환, 폐질환 (천식, 만성 기관지염), 신장질환 (신장염, 만성 심부전), 관절질환 (류마티즘, 관절염), 뇌질환 (알츠하이머, 파킨슨병, 기억감퇴, 우울증, 뇌졸증), 눈질환 (백내장, 망막질환), 심혈관질환(동맥경화, 고혈압, 허혈, 심근증, 심정지), 태아이상 (임신중독증, 자궁내성장저하), 신경퇴행성 질환을 비롯한 수많은 질병을 촉진한다고 알려졌다.In addition, excessive reactive oxygen species (ROS) in the body cause oxidative stress and cause inflammatory diseases, sepsis, cancer, aging, skin aging, sarcopenia, autoimmune diseases, lung diseases (asthma, chronic bronchitis), kidney disease (nephritis, chronic heart failure), joint disease (rheumatism, arthritis), brain disease (Alzheimer's, Parkinson's disease, memory loss, depression, stroke), eye disease (cataract, retinal disease), cardiovascular disease (arteriosclerosis, hypertension, ischemia, Cardiomyopathy, cardiac arrest), fetal abnormalities (pregnancy poisoning, endometriosis), and neurodegenerative diseases are known to promote numerous diseases.
한편, 사람을 포함한 동물의 위장관 내에서 숙주의 장내 미생물 환경을 개선하여 숙주의 건강에 유익한 영향을 주는 살아있는 미생물을 통칭하여 프로바이오틱스(probiotics)라고 한다. 프로바이오틱스로서 효과가 있기 위해서는 경구로 섭취될 때, 대부분이 소장에 도달해서 장 표면에 부착되어야 하므로, 기본적으로 내산성, 내담즙성 및 장 상피세포 부착능력이 우수하여야 한다. 유산균은 인체의 소화계에 공생하면서 섬유질 및 복합 단백질들을 분해하여 중요한 영양성분으로 만드는 역할을 담당하기 때문에 프로바이오틱스로 사용된다. 유산균은 장내 정상균총의 유지, 장내 균총의 개선, 항당뇨 및 항고지혈증 효과, 발암 억제, 대장염 억제, 그리고 숙주의 면역체계의 비특이적 활성 등의 효과를 나타낸다고 보고되고 있다. 그 중에서도 락토바실러스 속 균주는 인체의 장내에 서식하는 정상 미생물 군집의 주요 구성원으로서, 건강한 소화기관과 질 내 환경을 유지하는 데 있어서 중요한 것으로 오래전부터 알려져 왔고 미국의 공중건강 가이드라인(U.S. Public Health Service guidelines)에 의하면, 현재 미국 균주 기탁기관(ATCC)에 기탁된 락토바실러스 균주 모두 인체나 동물에 질병을 유발할 잠재적 위험에 대해서는 알려진 것이 없다고 인정되는 '안정수준(Bio-safty Level) 1'로 분류되어 있다. On the other hand, living microorganisms that have a beneficial effect on the health of the host by improving the intestinal microbial environment of the host in the gastrointestinal tract of animals including humans are collectively called probiotics. In order to be effective as a probiotic, when ingested orally, most of it must reach the small intestine and adhere to the intestinal surface, so it must have excellent acid resistance, bile resistance and intestinal epithelial cell adhesion ability. Lactic acid bacteria are used as probiotics because they play a role in making important nutrients by decomposing fiber and complex proteins while coexisting with the human digestive system. It is reported that lactic acid bacteria exhibit effects such as maintenance of normal intestinal flora, improvement of intestinal flora, anti-diabetic and anti-hyperlipidemic effects, carcinogenesis inhibition, colitis inhibition, and non-specific activity of the host's immune system. Among them, Lactobacillus spp. is a major member of the normal microbial community that inhabits the intestine of the human body, and has long been known to be important in maintaining a healthy digestive system and vaginal environment. According to guidelines), all of the Lactobacillus strains currently deposited with the US strain depository (ATCC) are classified as 'Bio-safety Level 1', which is recognized as not known about the potential risk of causing diseases in humans or animals. have.
이러한 유산균의 다양한 생리활성이 알려지면서, 최근 인체에 안전하면서도 기능이 우수한 유산균 균주를 개발하고 이를 의약품 또는 기능성 식품으로 적용하려는 연구가 활발하게 진행되고 있다.As the various physiological activities of these lactic acid bacteria are known, research to develop lactic acid bacteria strains that are safe for the human body and have excellent functions and apply them as pharmaceuticals or functional foods are being actively conducted.
이에 본 발명자들은 항산화 활성이 우수한 프로바이오틱스 균주를 선별하고자 연구를 수행한 결과, 새롭게 동정된 락토바실러스 애시도필러스 MG4559 균주가 항산화 활성이 우수함을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming that the newly identified Lactobacillus acidophilus MG4559 strain has excellent antioxidant activity as a result of conducting a study to select a probiotic strain having excellent antioxidant activity.
따라서, 본 발명의 목적은 항산화 활성을 갖는 신규한 균주 및 이의 용도를 제공하는 것이다. Accordingly, it is an object of the present invention to provide novel strains having antioxidant activity and uses thereof.
상기 목적을 달성하기 위하여, 본 발명은 항산화 활성을 갖는 락토바실러스 애시도필러스 (Lactobacillus acidophilus) MG4559 균주를 제공한다.In order to achieve the above object, the present invention provides a Lactobacillus acidophilus MG4559 strain having antioxidant activity.
또한, 본 발명은 상기 락토바실러스 애시도필러스 MG4559 균주 또는 균주 배양액을 포함하는 항산화용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for antioxidants comprising the Lactobacillus acidophilus MG4559 strain or a culture medium of the Lactobacillus acidophilus.
또한, 본 발명은 상기 락토바실러스 애시도필러스 MG4559 균주 또는 균주 배양액을 포함하는 항산화용 건강보조식품을 제공한다.In addition, the present invention provides a dietary supplement for antioxidants comprising the Lactobacillus acidophilus MG4559 strain or a culture solution of the Lactobacillus acidophilus.
또한, 본 발명은 상기 락토바실러스 애시도필러스 MG4559 균주 또는 균주 배양액을 포함하는 항산화용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for antioxidants comprising the Lactobacillus acidophilus MG4559 strain or a culture solution of the strain.
본 발명의 락토바실러스 애시도필러스 MG4559 균주는 우수한 산화 질소 생성 억제능 및 DPPH, ABTS 라디칼 소거 활성을 나타내고, COX-2 및 iNOS 유전자 발현을 억제하는 효과를 가지고 있으며, 특히 열처리를 통한 사균체에서도 우수한 항산화 효과를 나타내는바, 식품 또는 화장품 등으로 다양하게 활용될 수 있다.The Lactobacillus acidophilus MG4559 strain of the present invention exhibits excellent nitric oxide production inhibitory ability and DPPH and ABTS radical scavenging activity, has the effect of inhibiting COX-2 and iNOS gene expression, and is particularly excellent in dead cells through heat treatment Since it exhibits an antioxidant effect, it can be used in various ways as food or cosmetics.
도 1은 DPPH 라디칼 소거 활성 (상단) 및 ABTS 라디칼 소거 활성 (하단)을 확인한 결과를 나타낸 도이다.
도 2는 iNOS (상단) 및 COX-2 (하단) 유전자 발현을 확인한 결과를 나타낸 도이다.1 is a diagram showing the results of confirming DPPH radical scavenging activity (top) and ABTS radical scavenging activity (bottom).
2 is a diagram showing the results of confirming iNOS (upper) and COX-2 (lower) gene expression.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 항산화 활성을 갖는 락토바실러스 애시도필러스 (Lactobacillus acidophilus) MG4559 균주를 제공한다.The present invention provides a Lactobacillus acidophilus MG4559 strain having antioxidant activity.
본 발명자들은 인간 유아의 분변에서 분리된 유산균 중에서 산화 질소 생성 억제능이 우수하며, DPPH 및 ABTS 라디칼 소거 활성이 우수하고, COX-2 및 iNOS 유전자 발현을 억제하는 효과를 가지고 있는 균주를 새롭게 동정하였으며, 상기 균주가 락토바실러스 애시도필러스에 속함을 확인하였다. 이에 본 발명자들은 상기 균주를 Lactobacillus acidophilus MG4559로 명명하고 2021년 1월 6일 한국생명공학연구원 생물자원센터(Korean collection for type culture, 한국)에 기탁하고 수탁번호 KCTC14439BP를 부여받았다. The present inventors have newly identified strains having excellent nitric oxide production inhibitory ability, excellent DPPH and ABTS radical scavenging activity, and the effect of inhibiting COX-2 and iNOS gene expression among lactic acid bacteria isolated from human infant feces, It was confirmed that the strain belongs to Lactobacillus acidophilus. Accordingly, the present inventors named the strain Lactobacillus acidophilus MG4559 and deposited it at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center (Korean collection for type culture, Korea) on January 6, 2021, and was given an accession number KCTC14439BP.
특히, 본 발명에 따른 락토바실러스 애시도필러스 MG4559 균주는 열처리를 통한 사균체에서도 우수한 항산화 효과를 나타내는바 프로바이오틱스에 적합하므로 항산화 조성물로 다양하게 활용될 수 있다.In particular, the Lactobacillus acidophilus MG4559 strain according to the present invention can be used in various ways as an antioxidant composition because it is suitable for probiotics as it is suitable for probiotics as it shows an excellent antioxidant effect even on dead cells through heat treatment.
이에 본 발명은 락토바실러스 애시도필러스 MG4559 균주 또는 균주 배양액을 포함하는 항산화용 식품 조성물을 제공한다.Accordingly, the present invention provides a food composition for antioxidants comprising a Lactobacillus acidophilus MG4559 strain or a culture solution of the strain.
본 발명에 있어서, 상기 균주는 생균 뿐만 아니라 사균체의 형태로 포함될 수 있다. 상기 "사균체"란 생균의 반대되는 개념으로서 발효를 통해 얻어진 생균과 대사산물들을 열처리 등에 의해 균의 성장이 일어나지 못하도 록 한 형태를 의미한다. 사균체는 세포질(cytoplasm), 세포벽(cell wall), 박테리오신(bacteriocin) 등의 항균활성 물질, 다당류(polysaccharide), 및/또는 유기산 등을 포함할 수 있다. 본 발명의 일 실시예에서는 열처리를 통해 사균체를 수득하였다. In the present invention, the strain may be included in the form of live cells as well as dead cells. The term "dead cells" is the opposite concept of live cells, and refers to a form in which live cells and metabolites obtained through fermentation are prevented from growing by heat treatment or the like. The dead cells may include cytoplasm, cell wall, antibacterial active substances such as bacteriocin, polysaccharide, and/or organic acid. In one embodiment of the present invention, dead cells were obtained through heat treatment.
본 발명에 있어서, "배양액"은 락토바실러스 애시도필러스 MG4559 균주가 시험관 내에서 성장 및 생존할 수 있도록 영양분을 공급할 수 있는 배지에 상기 균주를 일정기간 배양하여 얻는 상기 균주, 이의 대사물, 여분의 영양분 등을 포함하는 전체 배지를 의미하나, 균주 배양 후 균주를 제거한 상등액, 이들의 추출물 및 분획물을 모두 포함하는 개념이다. 상기 배양액 중 균체를 제거한 액체를 "상등액" 또는 “무세포 상등액”이라고도 하며, 배양액을 일정시간 가만히 두어 하층에 가라앉은 부분을 제외한 상층의 액체만을 취하거나, 여과를 통해 균체를 제거하거나, 배양액을 원심분리하여 하부의 침전을 제거하고 상부의 액체만을 취하여 획득할 수 있다. 또한, 상기 배양액은 발효물을 포함할 수 있다. 일 예에서 상기 배양물은 상기 균주를 배지에서 배양한 발효물일 수 있다. 상기 "발효물"은 미생물을 이용한 유기물질의 효소적 또는 대사적 분해의 결과물을 의미한다. 본 발명에 있어서, "발효"는 미생물을 이용한 유기물질의 효소적 또는 대사적 분해를 포함하는 모든 활성 또는 과정 중 부패 반응이 아닌 것을 의미할 수 있다. 상기 배양액은 액체 배지뿐만 아니라 이의 건조물의 형태일 수 있다. In the present invention, the "culture solution" is the strain obtained by culturing the strain for a certain period of time in a medium capable of supplying nutrients so that the Lactobacillus acidophilus MG4559 strain can grow and survive in vitro, the strain, its metabolites, and extra It means the entire medium containing nutrients, etc., but is a concept including all of the supernatant, extracts and fractions thereof after strain culture. The liquid from which the cells are removed from the culture medium is also called "supernatant" or "cell-free supernatant", and the culture medium is left for a certain period of time to take only the liquid from the upper layer except for the part that has sunk to the lower layer, to remove the cells through filtration, or to drain the culture solution. It can be obtained by removing the sediment at the bottom by centrifugation and taking only the liquid at the top. In addition, the culture medium may include a fermented product. In one example, the culture may be a fermented product of the strain in a medium. The “fermented product” refers to a result of enzymatic or metabolic degradation of organic materials using microorganisms. In the present invention, "fermentation" may mean that it is not a spoilage reaction during any activity or process including enzymatic or metabolic degradation of organic materials using microorganisms. The culture medium may be in the form of a liquid medium as well as a dried product thereof.
본 발명의 항산화용 식품 조성물에 있어, 상기 균주 또는 배양액은 바람직하게 항산화용 식품 조성물 대비 0.00001~50 중량%로 포함될 수 있다. 상기 함량이 0.00001 중량% 미만일 경우에는 그 효과가 미비하고, 50 중량%를 초과하는 경우에는 사용량 대비 효과 증가가 미미하여 비경제적이다. In the antioxidant food composition of the present invention, the strain or culture solution may preferably be included in an amount of 0.00001 to 50% by weight compared to the antioxidant food composition. When the content is less than 0.00001% by weight, the effect is insignificant, and when it exceeds 50% by weight, the increase in the effect relative to the amount used is insignificant, which is uneconomical.
본 발명의 항산화용 식품 조성물은 일 예로 육류, 곡류, 카페인 음료, 일반음료, 초콜릿, 빵류, 스낵류, 과자류, 사탕, 피자, 젤리, 면류, 껌류, 유제품류, 아이스크림류, 알코올성 음료, 술, 비타민 복합제 및 그 밖의 건강보조식품류 중 선택되는 어느 하나일 수 있으나, 반드시 이에 한정되는 것은 아니다. Antioxidant food composition of the present invention is, for example, meat, grains, caffeinated beverages, general drinks, chocolate, breads, snacks, confectionery, candy, pizza, jelly, noodles, gums, dairy products, ice cream, alcoholic beverages, alcohol, vitamins It may be any one selected from combination drugs and other health supplements, but is not necessarily limited thereto.
또한, 본 발명은 락토바실러스 애시도필러스 MG4559 균주 또는 균주 배양액을 포함하는 항산화용 건강보조식품을 제공한다.In addition, the present invention provides a dietary supplement for antioxidants comprising a Lactobacillus acidophilus MG4559 strain or a culture solution of the strain.
본 발명에서, “건강보조식품” 또는 '건강기능식품'이란 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.In the present invention, “health supplement” or “health functional food” means a food manufactured and processed using raw materials or ingredients useful for the human body according to the Health Functional Food Act, and is referred to as “functional”. refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological effects.
본 발명의 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.The food composition of the present invention may contain conventional food additives, and the suitability as the "food additive" is determined according to the general rules and general test methods of food additives approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the standards and standards related to the item. The items listed in the "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixed preparations such as sodium L-glutamate preparation, noodle-added alkali agent, preservative agent, and tar color agent can be mentioned.
본 발명의 조성물을 식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. When the composition of the present invention is used as a food additive, the composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
본 발명의 식품 조성물은 정제, 캡슐, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.The food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like.
본 발명의 조성물이 음료로 제조될 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토오스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml 당 일반적으로 약 0.01 내지 10 g, 바람직하게는 약 0.01 내지 0.1 g이다.When the composition of the present invention is prepared as a beverage, it may contain various flavoring agents or natural carbohydrates as an additional component like a conventional beverage. As the above-mentioned natural carbohydrates, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharin and aspartame may be used. The proportion of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, Carbonating agents used in carbonated beverages, etc. may be included. In addition, the composition of the present invention may contain the pulp for the production of natural fruit juice, fruit juice beverage, and vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
한편, 본 발명은 락토바실러스 애시도필러스 MG4559 균주 또는 균주 배양액을 포함하는 항산화용 화장료 조성물을 제공한다.On the other hand, the present invention provides a cosmetic composition for antioxidants comprising a Lactobacillus acidophilus MG4559 strain or a culture solution of the strain.
본 발명에 있어서, 상기 유효성분은, 바람직하게 화장료 조성물 전체 중량에 대하여 0.00001~30.0중량%가 함유될 수 있다. 상기 함량이 0.00001중량% 미만인 경우에는 피부 항산화 효과가 나타나지 않고, 30.0중량% 초과할 경우 함유량 증가에 따른 뚜렷한 효과가 증가하지 않는다.In the present invention, the active ingredient, preferably, may be contained in an amount of 0.00001 to 30.0% by weight based on the total weight of the cosmetic composition. When the content is less than 0.00001% by weight, the skin antioxidant effect does not appear, and when it exceeds 30.0% by weight, a distinct effect according to the increase in the content does not increase.
본 발명의 화장료 조성물은 화장료 조성물에 통상적으로 이용되는 성분들을 추가적으로 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The cosmetic composition of the present invention may additionally include components commonly used in the cosmetic composition, for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 팩, 마사지크림 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream, spray, etc., but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, a nourishing lotion, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, or a powder.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. This can be used.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이 소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다. When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate. , propylene glycol, 1,3-butyl glycol oil, glycerol fatty ester, polyethylene glycol or fatty acid ester of sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanth may be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydro It may contain a propellant such as carbon, propane/butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is cleansing containing surfactant, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, Fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형 비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비 함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing formulation, or a surfactant-free cleansing formulation, it may be applied to the skin and then wiped off, removed, or washed off with water. As a specific example, the soap is liquid soap, powdered soap, solid soap, and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel, and cleansing pack, and the surfactant-free cleansing formulation is a cleansing cream , cleansing lotion, cleansing water, and cleansing gel, but not limited thereto.
중복되는 내용은 본 명세서의 복잡성을 고려하여 생락하며, 본 명세서에서 달리 정의되지 않은 용어들은 본 발명이 속하는 기술분야에서 통상적으로 사용되는 의미를 갖는 것이다. 본 명세서에서 달리 정의되지 않은 용어들은 본 발명이 속하는 기술분야에서 통상적으로 사용되는 의미를 갖는 것이다.Redundant content is omitted in consideration of the complexity of the present specification, and terms not defined otherwise in the present specification have the meanings commonly used in the art to which the present invention pertains. Terms not otherwise defined herein have meanings commonly used in the art to which the present invention pertains.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of Examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited by the following examples.
실시예 1. 유산균 사균체 시료 준비Example 1. Preparation of lactic acid bacteria dead cells sample
㈜메디오젠 (Mediogen Co. Ltd, Chungju, Korea)에서 보유하고 있는 유산균 균주 63종을 이용하였으며, 구체적인 정보는 표 1에 나타내었다. 인간과 발효 식품에서 분리된 유산균은 16S rRNA 유전자 연기서열 분석법을 통해 동정되었으며, 선별된 균주는 MRS 배지에 접종하여 37℃에서 배양 및 유지되었다. 63 strains of lactic acid bacteria owned by Mediogen Co. Ltd, Chungju, Korea were used, and detailed information is shown in Table 1. Lactic acid bacteria isolated from humans and fermented foods were identified through 16S rRNA gene smoke sequencing, and the selected strains were inoculated into MRS medium and cultured and maintained at 37°C.
한편, 살아있는 프로바이오틱스를 식품 등에 활용하기 위해서는 저온 및 혐기성 조건이 요구되는바 포장 및 유통 비용이 증가한다. 따라서 열처리를 통해 사균체로 제조하더라도 유산균의 기능이 그대로 유지될 경우에는 프로바이오틱스를 이용한 식품의 가공 단계를 단순화할 수 있는 장점을 가지고 있다. 이에 본 발명자들은 유산균의 사균체를 제조하기 위하여, 하룻밤 배양한 균주를 90℃에서 30분간 열처리하여 사멸시켰다. 이를 원심분리 (12000×g, 5분)한 후, 펠렛을 PBS로 3회 세척하였다. 세척된 균체를 DMEM에 현탁한 후, -40℃에서 1시간 동안 1차 건조하고, -40℃에서 20℃까지 단계적으로 온도를 상승시키면서 24시간 동안 2차 건조하여, 건조물을 수득하였다. 이후 목적 농도의 사균체의 건조물을 수득하여 실험에 사용하였다. On the other hand, in order to utilize live probiotics in food, etc., low temperature and anaerobic conditions are required, which increases packaging and distribution costs. Therefore, if the function of lactic acid bacteria is maintained even if it is manufactured as dead cells through heat treatment, it has the advantage of simplifying the processing step of food using probiotics. Accordingly, the present inventors killed the strains cultured overnight at 90° C. for 30 minutes to prepare dead cells of lactic acid bacteria. After centrifugation (12000×g, 5 min), the pellet was washed 3 times with PBS. After the washed cells were suspended in DMEM, the cells were first dried at -40°C for 1 hour, and then dried secondarily for 24 hours while increasing the temperature stepwise from -40°C to 20°C to obtain a dried product. Thereafter, a dried product of dead cells of the desired concentration was obtained and used in the experiment.
실시예 2. NO 생산 억제능 스크리닝Example 2. NO production inhibitory ability screening
마우스 대식세포인 RAW 264.7 세포주는 한국세포주은행에서 수득하였다. RAW 264.7 세포를 37 ℃, 5 % CO2의 조건에서 배양하고, 3 일마다 95 %까지 계대 배양하였다. 세포 배양 배지로는 10 % FBS, 1% 페니실린/스트렙토마이신이 포함된 DMEM 배지를 이용하였다.The RAW 264.7 cell line, a mouse macrophage, was obtained from the Korea Cell Line Bank. RAW 264.7 cells were cultured at 37° C., 5% CO 2 , and subcultured to 95% every 3 days. As a cell culture medium, DMEM medium containing 10% FBS and 1% penicillin/streptomycin was used.
NO 생산능을 측정하기 위하여, 다음과 같은 실험을 수행하였다. 먼저, RAW 264.7 세포를 96 웰 플레이트에 2×105 세포/웰의 농도로 씨딩하고, 1 μg/mL LPS로 자극한 다음 실시예 1에서 수득한 유산균 사균체(107 세포/웰)를 각 웰에 첨가하였다. 24 시간 배양한 후, Griess 시약을 사용하여 세포 배양 상청액의 아질산염의 양을 측정하여 NO 농도를 측정하였다. 550 nm 파장에서 흡광도 측정은 Epoch 2 마이크로플레이트 리더(BioTek, USA)를 사용하여 확인하였다. 모든 실험에 대한 블랭크 대조군으로 신선한 배양 배지를 사용하였다. 그 결과를 표 1에 나타내었다. In order to measure NO production capacity, the following experiment was performed. First, RAW 264.7 cells were seeded in a 96-well plate at a concentration of 2×10 5 cells/well, stimulated with 1 μg/mL LPS, and then the lactic acid bacteria dead cells (10 7 cells/well) obtained in Example 1 were each seeded. added to the wells. After culturing for 24 hours, the NO concentration was determined by measuring the amount of nitrite in the cell culture supernatant using Griess reagent. Absorbance measurements at 550 nm wavelength were confirmed using an Epoch 2 microplate reader (BioTek, USA). Fresh culture medium was used as a blank control for all experiments. The results are shown in Table 1.
표 1에 나타낸 바와 같이, 실시예 1에 따른 63종의 유산균 사균체 중 L. acidophilus MG4559 균주가 약 86%의 우수한 산화 질소 생성 억제 활성을 나타냄을 확인하였다. As shown in Table 1, it was confirmed that the L. acidophilus MG4559 strain among 63 lactic acid bacteria killed cells according to Example 1 exhibited an excellent nitric oxide production inhibitory activity of about 86%.
상기 MG4559 균주는 인간 유아의 분변에서 분리된 유산균으로, 서열번호 1의 16S rRNA를 가지고 있음을 확인하였다. BLAST(Basic Local Alignment Search Tool)를 이용하여 NCBI의 GenBank 데이터베이스에 등록된 정보와 비교한 결과, 락토바실러스 애시도필러스로 동정되었으며, 본 발명자들은 이를 Lactobacillus acidophilus MG4559로 명명하고, 2021년 1월 6일 생물자원센터(Korean collection for type culture, 한국)에 기탁하고 수탁번호 KCTC14439BP를 부여받았다. The MG4559 strain is a lactic acid bacterium isolated from human infant feces, and it was confirmed that it has 16S rRNA of SEQ ID NO: 1. As a result of comparison with information registered in NCBI's GenBank database using BLAST (Basic Local Alignment Search Tool), it was identified as Lactobacillus acidophilus, and the present inventors named it Lactobacillus acidophilus MG4559, and on January 6, 2021 It was deposited at the Center for Biological Resources (Korean collection for type culture, Korea) and was given an accession number KCTC14439BP.
실시예 3. 세포 생존능 확인Example 3. Confirmation of cell viability
실시예 2에서 선별된 락토바실러스 애시도필러스 MG4559 균주가 세포 생존에 미치는 영향을 확인하기 위하여, 다음과 같은 실험을 수행하였다. RAW 264.7 세포에 락토바실러스 애시도필러스 MG4559 균주의 사균체를 2×107 세포/웰 및 2×108 세포/웰의 농도로 각각 첨가하여 배양한 후, PBS로 2회 세척하였다. PBS에 용해된 100 μL의 MTT 시약 (3-[4,5-Dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide, 0.5 mg/mL)을 각 웰에 첨가하였다. 배양 1 시간 후, MTT 시약을 버리고 100 μL의 디메틸 설폭사이드 (DMSO; Sigma, USA)를 첨가하여 MTT 시약과 살아있는 세포의 대사 산물 사이에 반응물로 형성된 포르마잔을 용해시켰다. 흡광도는 570nm 파장에서 측정하였으며, 음성 대조군의 결과와 비교하여 다음과 같이 세포 독성을 계산하였다. 그 결과를 표 2에 나타내었다. In order to confirm the effect of the Lactobacillus acidophilus MG4559 strain selected in Example 2 on cell survival, the following experiment was performed. The dead cells of the Lactobacillus acidophilus MG4559 strain were added to RAW 264.7 cells at a concentration of 2×10 7 cells/well and 2×10 8 cells/well, respectively, and cultured, followed by washing twice with PBS. 100 μL of MTT reagent (3-[4,5-Dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide, 0.5 mg/mL) dissolved in PBS was added to each well. After 1 h of incubation, the MTT reagent was discarded and 100 μL of dimethyl sulfoxide (DMSO; Sigma, USA) was added to dissolve the formazan formed as a reaction between the MTT reagent and the metabolites of living cells. Absorbance was measured at a wavelength of 570 nm, and cytotoxicity was calculated as follows compared with the result of the negative control. The results are shown in Table 2.
* 세포 생존율 (%) = (샘플 / 음성 대조군) × 100 * Cell viability (%) = (sample / negative control) × 100
표 2에 나타낸 바와 같이, 선별된 락토바실러스 애시도필러스 MG4559 균주의 사균체는 RAW 264.7 세포에 영향이 없음, 즉 세포 독성이 없어 안전한 균주임을 확인하였다. As shown in Table 2, the dead cells of the selected Lactobacillus acidophilus MG4559 strain had no effect on RAW 264.7 cells, that is, it was confirmed that it was a safe strain without cytotoxicity.
실시예 4. 항산화 활성 Example 4. Antioxidant activity
실시예 2에서 선별된 락토바실러스 애시도필러스 MG4559 균주의 항산화 활성을 추가적으로 확인하기 위하여 두 가지 실험을 수행하였다. In order to further confirm the antioxidant activity of the Lactobacillus acidophilus MG4559 strain selected in Example 2, two experiments were performed.
먼저, DPPH(2,2-diphenyl-1-picrylhydrazyl) 라디칼 소거 분석을 수행하였다. 보다 구체적으로, 대략 1.0의 OD600으로 조정된 유산균 사균체를 0.05 mM DPPH 용액 (1:2 v/v)에 첨가하고 잘 혼합하였다. 그 후, 혼합물을 암실에서 30 분 동안 실온에서 유지하였다. 음성 대조군은 DPPH 용액에 첨가된 에탄올을 사용하였다. 각 시료의 흡광도는 517 nm 파장에서 정량화하였으며, 샘플 분석은 세 번 수행하였다. 다음과 같이 항산화 활성을 계산하였으며, 아스코르브산 (10μg/mL, Contol로 사용)을 양성 대조군으로 사용하였다. 그 결과를 도 1 상단에 나타내었다. First, DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging analysis was performed. More specifically, lactic acid bacteria dead cells adjusted to an OD600 of approximately 1.0 were added to 0.05 mM DPPH solution (1:2 v/v) and mixed well. After that, the mixture was kept at room temperature for 30 minutes in the dark. As a negative control, ethanol added to the DPPH solution was used. The absorbance of each sample was quantified at a wavelength of 517 nm, and sample analysis was performed three times. Antioxidant activity was calculated as follows, and ascorbic acid (10 μg/mL, used as Contol) was used as a positive control. The results are shown at the top of FIG. 1 .
* 소거능(%) = (Ac-As) / Ac × 100* Scavenging ability (%) = (Ac-As) / Ac × 100
(As는 시료의 흡광도이고, Ac는 음성대조군의 흡광도임)(As is the absorbance of the sample, Ac is the absorbance of the negative control)
다음으로, ABTS(2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) 라디칼 소거 활성을 측정하였다. 라디칼 양이온은 7 mM의 ABTS와 2.45 mM과 황산 칼륨(1:1 v/v)을 혼합하여 제조하고, 혼합물을 24 시간 동안 어두운 곳 및 실온에서 유지하였다. 그 후, 50 μL의 유산균 사균체와 100 μL의 ABTS 용액을 혼합하고 실온에서 10 분 동안 배양하였다. 혼합물의 흡광도는 734 nm 파장에서 측정되었으며, 샘플 분석은 세 번 수행하였다. 다음과 같이 항산화 활성을 계산하였으며, 아스코르브산 (10μg/mL, Contol로 사용)을 양성 대조군으로 사용하였다. 그 결과를 도 1 하단에 나타내었다. Next, the radical scavenging activity of ABTS (2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) was measured. The radical cation was 7 mM ABTS and 2.45 mM potassium sulfate (1:1 v/v). ), and keep the mixture in the dark and at room temperature for 24 hours.After that, 50 μL of lactic acid bacteria and 100 μL of ABTS solution are mixed and incubated at room temperature for 10 minutes.The absorbance of the mixture is Measured at 734 nm wavelength, sample analysis was performed three times.Antioxidant activity was calculated as follows, and ascorbic acid (10 μg/mL, used as Contol) was used as a positive control.The results are shown at the bottom of FIG. It was.
* 소거능(%) = (Ac-As) / Ac × 100* Scavenging ability (%) = (Ac-As) / Ac × 100
(As는 시료의 흡광도이고, Ac는 음성대조군의 흡광도임)(As is the absorbance of the sample, Ac is the absorbance of the negative control)
도 1에 나타낸 바와 같이, 락토바실러스 애시도필러스 MG4559 균주의 사균체가 우수한 라디칼 소거 활성, 즉 항산화 활성이 있음을 확인하였다. As shown in FIG. 1 , it was confirmed that the dead cells of the Lactobacillus acidophilus MG4559 strain had excellent radical scavenging activity, that is, antioxidant activity.
실시예 5. RT-PCR 분석Example 5. RT-PCR analysis
실시예 4의 항산화 실험에 더하여, 관련 유전자 발현에 미치는 영향을 확인하기 위하여 RT-PCR을 수행하였다. RAW 264.7 세포에 락토바실러스 애시도필러스 MG4559 균주의 사균체를 2×105 세포/웰의 농도로 첨가하고 배양하였다. 상기 세포로부터 TRI REGENT ™(Sigma Chemical Co., St. Louis, MO)를 사용하여 총 RNA를 추출하였으며, COX-2 및 iNOS에 대한 각 프라이머와 1 μg의 RNA를 ONE-STEP RT-PCR PreMix™와 혼합하였다. 상기 혼합물을 95 ℃에서 5 분 동안 사전 변성하고; 95 ℃에서 15초, 61 ℃에서 30초, 61 ℃에서 30초 반응시키는 과정을 40 사이클 반복하고; 61 ℃에서 30 초 동안 최종 신장하였다. 유전자 발현을 정량하기 위한 대조군으로 GAPDH를 이용하였으며, 프라이머 서열을 표 3에 나타내었다. 실험 결과를 도 2에 나타내었다. In addition to the antioxidant experiment of Example 4, RT-PCR was performed to confirm the effect on the expression of related genes. The dead cells of the Lactobacillus acidophilus MG4559 strain were added to RAW 264.7 cells at a concentration of 2×10 5 cells/well and cultured. Total RNA was extracted from the cells using TRI REGENT ™ (Sigma Chemical Co., St. Louis, MO), and each primer for COX-2 and iNOS and 1 μg of RNA were mixed with ONE-STEP RT-PCR PreMix™. was mixed with The mixture was pre-denatured at 95 °C for 5 minutes; The process of reacting at 95° C. for 15 seconds, at 61° C. for 30 seconds, and at 61° C. for 30 seconds was repeated for 40 cycles; Final extension was carried out at 61° C. for 30 seconds. GAPDH was used as a control for quantifying gene expression, and the primer sequences are shown in Table 3. The experimental results are shown in FIG. 2 .
도 2에 나타낸 바와 같이, LPS 유도에 의해 iNOS 및 COX-2 유전자 발현이 현저하게 증가하였으며, 본 발명에 따른 락토바실러스 애시도필러스 MG4559 균주의 사균체 처리에 의해 증가된 유전자 발현이 현저하게 억제됨을 확인하였다. As shown in Figure 2, iNOS and COX-2 gene expression was remarkably increased by LPS induction, and the increased gene expression was significantly inhibited by the dead cell treatment of the Lactobacillus acidophilus MG4559 strain according to the present invention. was confirmed.
이상의 실험을 통하여, 본 발명에 따른 락토바실러스 애시도필러스 MG4559 균주는 생균 뿐만 아니라 사균체로도 활용될 수 있으며, 현저하게 우수한 항산화 효과를 나타내는바, 프로바이오틱스로서 항산화 관련 조성물에 다양하게 활용될 수 있음을 확인하였다. Through the above experiments, the Lactobacillus acidophilus MG4559 strain according to the present invention can be utilized not only as a live cell but also as a dead cell, and exhibits a remarkably excellent antioxidant effect. confirmed that there is.
이상, 본 발명내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.Above, specific parts of the present invention have been described in detail, for those of ordinary skill in the art, these specific descriptions are only preferred embodiments, and it is clear that the scope of the present invention is not limited thereby. something to do. Accordingly, it is intended that the substantial scope of the present invention be defined by the appended claims and their equivalents.
<110> MEDIOGEN Co.,Ltd. <120> Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus <130> 1-32 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1435 <212> DNA <213> Lactobacillus acidophilus <400> 1 tgcagtcgag cgagctgacc aacagattca cttcggtgat gacgttggga acgcgagcgg 60 cggatgggtg agtaacacgt ggggaacctg ccccatagtc tgggatacca cttggaaaca 120 ggtgctaata ccggataaga aagcagatcg catgatcagc ttataaaagg cggcgtaagc 180 tgtcgctatg ggatggcccc gcggtgcatt agctagttgg tagggtaacg gcctaccaag 240 gcaatgatgc atagccgagt tgagagactg atcggccaca ttgggactga gacacggccc 300 aaactcctac gggaggcagc agtagggaat cttccacaat ggacgaaagt ctgatggagc 360 aacgccgcgt gagtgaagaa ggttttcgga tcgtaaagct ctgttgttgg tgaagaagga 420 tagaggtagt aactggcctt tatttgacgg taatcaacca gaaagtcacg gctaactacg 480 tgccagcagc cgcggtaata cgtaggtggc aagcgttgtc cggatttatt gggcgtaaag 540 cgagcgcagg cggaagaata agtctgatgt gaaagccctc ggcttaaccg aggaactgca 600 tcggaaactg tttttcttga gtgcagaaga ggagagtgga actccatgtg tagcggtgga 660 atgcgtagat atatggaaga acaccagtgg cgaaggcggc tctctggtct gcaactgacg 720 ctgaggctcg aaagcatggg tagcgaacag gattagatac cctggtagtc catgccgtaa 780 acgatgagtg ctaagtgttg ggaggtttcc gcctctcagt gctgcagcta acgcattaag 840 cactccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac gggggcccgc 900 acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac caggtcttga 960 catctagtgc aatccgtaga gatacggagt tcccttcggg gacactaaga caggtggtgc 1020 atggctgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg agcgcaaccc 1080 ttgtcattag ttgccagcat taagttgggc actctaatga gactgccggt gacaaaccgg 1140 aggaaggtgg ggatgacgtc aagtcatcat gccccttatg acctgggcta cacacgtgct 1200 acaatggaca gtacaacgag gagcaagcct gcgaaggcaa gcgaatctct taaagctgtt 1260 ctcagttcgg actgcagtct gcaactcgac tgcacgaagc tggaatcgct agtaatcgcg 1320 gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg tcacaccatg 1380 ggagtctgca atgcccaaag ccggtggcct aaccttcggg aaggagccgt ctaag 1435 <110> MEDIOGEN Co., Ltd. <120> Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus <130> 1-32 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1435 <212> DNA <213> Lactobacillus acidophilus <400> 1 tgcagtcgag cgagctgacc aacagattca cttcggtgat gacgttggga acgcgagcgg 60 cggatgggtg agtaacacgt ggggaacctg ccccatagtc tgggatacca cttggaaaca 120 ggtgctaata ccggataaga aagcagatcg catgatcagc ttataaaagg cggcgtaagc 180 tgtcgctatg ggatggcccc gcggtgcatt agctagttgg tagggtaacg gcctaccaag 240 gcaatgatgc atagccgagt tgagagactg atcggccaca ttgggactga gacacggccc 300 aaactcctac gggaggcagc agtagggaat cttccacaat ggacgaaagt ctgatggagc 360 aacgccgcgt gagtgaagaa ggttttcgga tcgtaaagct ctgttgttgg tgaagaagga 420 tagaggtagt aactggcctt tatttgacgg taatcaacca gaaagtcacg gctaactacg 480 tgccagcagc cgcggtaata cgtaggtggc aagcgttgtc cggatttatt gggcgtaaag 540 cgagcgcagg cggaagaata agtctgatgt gaaagccctc ggcttaaccg aggaactgca 600 tcggaaactg tttttcttga gtgcagaaga ggagagtgga actccatgtg tagcggtgga 660 atgcgtagat atatggaaga acaccagtgg cgaaggcggc tctctggtct gcaactgacg 720 ctgaggctcg aaagcatggg tagcgaacag gattagatac cctggtagtc catgccgtaa 780 acgatgagtg ctaagtgttg ggaggtttcc gcctctcagt gctgcagcta acgcattaag 840 cactccgcct ggggagtacg accgcaaggt tgaaactcaa aggaattgac gggggcccgc 900 acaagcggtg gagcatgtgg tttaattcga agcaacgcga agaaccttac caggtcttga 960 catctagtgc aatccgtaga gatacggagt tcccttcggg gacactaaga caggtggtgc 1020 atggctgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg agcgcaaccc 1080 ttgtcattag ttgccagcat taagttgggc actctaatga gactgccggt gacaaaccgg 1140 aggaaggtgg ggatgacgtc aagtcatcat gccccttatg acctgggcta cacacgtgct 1200 acaatggaca gtacaacgag gagcaagcct gcgaaggcaa gcgaatctct taaagctgtt 1260 ctcagttcgg actgcagtct gcaactcgac tgcacgaagc tggaatcgct agtaatcgcg 1320 gatcagcacg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg tcacaccatg 1380 ggagtctgca atgcccaaag ccggtggcct aaccttcggg aaggagccgt ctaag 1435
Claims (8)
Accession number KCTC14439BP and deposited with, Lactobacillus acidophilus ( Lactobacillus acidophilus ) MG4559 strain having antioxidant activity.
The Lactobacillus acidophilus MG4559 strain according to claim 1, wherein the Lactobacillus acidophilus MG4559 strain is isolated from human infant feces.
A food composition for antioxidant comprising the Lactobacillus acidophilus MG4559 strain or strain culture solution of claim 1 or 2.
The food composition according to claim 3, wherein the strain is a dead cell.
The food composition according to claim 3, wherein the composition inhibits COX-2 or iNOS gene expression.
A health supplement for antioxidants comprising the Lactobacillus acidophilus MG4559 strain or strain culture solution of claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210020494A KR102310898B1 (en) | 2021-02-16 | 2021-02-16 | Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210020494A KR102310898B1 (en) | 2021-02-16 | 2021-02-16 | Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102310898B1 true KR102310898B1 (en) | 2021-10-08 |
Family
ID=78115720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210020494A KR102310898B1 (en) | 2021-02-16 | 2021-02-16 | Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102310898B1 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110000871A (en) * | 2009-06-29 | 2011-01-06 | 주식회사한국야쿠르트 | Antioxidative and antiinflammatory composition containing lactobacillus plantarum hy7711 as an effective factor |
| KR20110044966A (en) * | 2011-04-20 | 2011-05-03 | 주식회사 엘씨에스바이오텍 | Compositions for antioxidation |
| KR101239806B1 (en) | 2011-04-01 | 2013-03-06 | 주식회사한국야쿠르트 | The new Lactobacillus plantarum HY7712 stimulate immunity |
| KR101240192B1 (en) | 2010-11-24 | 2013-03-06 | 한국식품연구원 | Lactobacillus acidophilus K-59, extracts from ginseng-fermented products using K-59 for improving insulin secretion and manufacturing method thereof |
| KR20150005486A (en) * | 2014-11-19 | 2015-01-14 | 일동제약주식회사 | Method of preparing functional fermented turmeric gel having anti-oxidant, moisturizing and anti-biotic effect using a probiotic lactic acid bacteria and functional fermented turmeric gel prepared thereby |
| KR101627850B1 (en) | 2013-07-23 | 2016-06-07 | 서원대학교산학협력단 | Method of fermentation using complex strains and cosmetic composition comprising thereof |
| KR20170032816A (en) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | Novel lactic acid bacteria with various functionality and use thereof |
| KR20170111763A (en) | 2016-03-29 | 2017-10-12 | 전남대학교산학협력단 | Pharmaceutical Composition for Preventing or Treating Enteric Diseases Caused by Clostridium difficile Comprising Lactobacillus acidophilus KCNU |
-
2021
- 2021-02-16 KR KR1020210020494A patent/KR102310898B1/en active IP Right Grant
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110000871A (en) * | 2009-06-29 | 2011-01-06 | 주식회사한국야쿠르트 | Antioxidative and antiinflammatory composition containing lactobacillus plantarum hy7711 as an effective factor |
| KR101240192B1 (en) | 2010-11-24 | 2013-03-06 | 한국식품연구원 | Lactobacillus acidophilus K-59, extracts from ginseng-fermented products using K-59 for improving insulin secretion and manufacturing method thereof |
| KR101239806B1 (en) | 2011-04-01 | 2013-03-06 | 주식회사한국야쿠르트 | The new Lactobacillus plantarum HY7712 stimulate immunity |
| KR20110044966A (en) * | 2011-04-20 | 2011-05-03 | 주식회사 엘씨에스바이오텍 | Compositions for antioxidation |
| KR101627850B1 (en) | 2013-07-23 | 2016-06-07 | 서원대학교산학협력단 | Method of fermentation using complex strains and cosmetic composition comprising thereof |
| KR20150005486A (en) * | 2014-11-19 | 2015-01-14 | 일동제약주식회사 | Method of preparing functional fermented turmeric gel having anti-oxidant, moisturizing and anti-biotic effect using a probiotic lactic acid bacteria and functional fermented turmeric gel prepared thereby |
| KR20170032816A (en) * | 2015-09-15 | 2017-03-23 | 경희대학교 산학협력단 | Novel lactic acid bacteria with various functionality and use thereof |
| KR20170111763A (en) | 2016-03-29 | 2017-10-12 | 전남대학교산학협력단 | Pharmaceutical Composition for Preventing or Treating Enteric Diseases Caused by Clostridium difficile Comprising Lactobacillus acidophilus KCNU |
Non-Patent Citations (2)
| Title |
|---|
| GenBank Accession NO.MN400222.1(2019.09.10.)* * |
| Phytotherapy Research, Vol.32, pp.1950-1956(2018.)* * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10245291B2 (en) | Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof | |
| US9387228B2 (en) | Agent for prevention or amelioration of obesity | |
| JP2008179601A (en) | Cosmetic composition containing bacterium of genus lactobacillus | |
| KR20110000871A (en) | Antioxidative and antiinflammatory composition containing lactobacillus plantarum hy7711 as an effective factor | |
| JP7179343B2 (en) | Novel lactic acid strain and immunostimulant containing the same | |
| KR20160110829A (en) | The milk fermented product using Lactobacillus paracasei HY7301 for skin whitening and products containing thereof as effective component | |
| KR20220049069A (en) | Compositions comprising skin derived lactic acid bacteria having effects of anti-oxidation, anti-inflammation and whitening | |
| KR102421144B1 (en) | Bifidobacterium bifidum EPS DA-LAIM promoting the growth of lactobacillus and polysaccharide therefrom | |
| KR102424598B1 (en) | Lactobacillus pentosus OKBL-L.PE 1 strain having antioxidant activity, anti-inflammatory activity, skin whitening activity, antimicrobial activity against pathogenic microorganism and anti-thrombotic activity and uses thereof | |
| KR102263454B1 (en) | Skin derived novel lactic acid bacteria having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
| KR101677187B1 (en) | The Functional Health Drink For Improving The Intestine Function and Environment and Enhencing Immunity | |
| KR101743044B1 (en) | The Functional Health Food For Improving The Intestine Function and Environment and Enhencing Immunity | |
| KR101743043B1 (en) | Nano-Sized Lactic Acid Bacteria from Kimchi For Improving The Intestine Function and Environment | |
| KR102562507B1 (en) | Novel lactobacillus paracasei subsp. tolerans wikim0148 with potent anti-inflammatory activity and uses thereof | |
| KR102310898B1 (en) | Composition for anti-oxidant comprising dried powder of culture of Lactobacillus acidophilus | |
| KR102548092B1 (en) | Lactobacillus curvatus OKBL-L.CU 1 strain having antioxidant activity, antimicrobial activity, skin whitening activity, skin anti-wrinkle activity, anti-inflammatory activity and anti-cancer activity and uses thereof | |
| KR102511656B1 (en) | Lactobacillus plantarum OKBL-L.PL 1 strain having anti-inflammatory activity, skin whitening activity, antimicrobial activity against pathogenic microorganism and anti-thrombotic activity and uses thereof | |
| KR102333208B1 (en) | Skin-lightening Composition Using an Extract of Adlay Bran or Fermentation Product Thereof | |
| KR101768817B1 (en) | Food composition for anti-oxidation and inhanced immunity comprising chamomile flower extract short-term fermented by lactic acid bacteria and the method of preparation thereof | |
| JP7362081B2 (en) | Novel lactic acid bacteria strains and their uses | |
| KR102389753B1 (en) | Skin derived novel Lactobacillus plantarum subsp. shebah-202 strain having effects of enhancing skin barrier and anti-wrinkle and use thereof | |
| WO2022091193A1 (en) | Novel lactic acid bacterium derived from japanese beech inhabiting the shirakami mountainous region | |
| KR20160085235A (en) | The Functional Health Ice Cream For Improving The Intestine Function and Environment and Enhencing Immunity | |
| KR20240057227A (en) | Composition with Skin Whitening, Moisturizing, Barrier Strengthening, Exfoliating, and Itch Improvement Property Comprising Complex Strain of Lactobacillus sp. as Active Ingredient | |
| KR20240007373A (en) | Composition for Skin Moisturizing, Skin Barrier, Elasticity and Improving Skin Itching Comprising Lactobacillus Complex Strain as Active Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |